Viridian Therapeutics, Inc./DE Interest and Other Income
Viridian Therapeutics, Inc./DE (VRDN) reported Interest and Other Income of $6.55 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2025-08-06
- Viridian Therapeutics, Inc./DE interest and other income for the quarter ending 2025-06-30 was $6.55M, a 15.98% decline year-over-year.
- Viridian Therapeutics, Inc./DE interest and other income for the quarter ending 2025-03-31 was $7.54M, a 5.06% decline year-over-year.
- Viridian Therapeutics, Inc./DE interest and other income for the quarter ending 2024-12-31 was $8.61M, a 55.49% increase year-over-year.
- Viridian Therapeutics, Inc./DE interest and other income for the quarter ending 2024-09-30 was $7.79M, a 87.20% increase year-over-year.
- Viridian Therapeutics, Inc./DE interest and other income for fiscal 2024 was $32.13M, a 73.10% increase from fiscal 2023.
- Viridian Therapeutics, Inc./DE interest and other income for fiscal 2023 was $18.56M, a 277.60% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE interest and other income for fiscal 2022 was $4.92M, a 1445.91% increase from fiscal 2021.
- Viridian Therapeutics, Inc./DE interest and other income for fiscal 2021 was $318.00K.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2025-06-30 | $6.55M 10-Q · filed 2025-08-06 | $14.09M 10-Q · filed 2025-08-06 | $22.69M derived: sum of 3 quarters · filed 2025-08-06 | $30.49M derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | $7.54M 10-Q · filed 2025-05-06 | $16.14M derived: sum of 2 quarters · filed 2025-05-06 | $23.94M derived: sum of 3 quarters · filed 2025-05-06 | $31.73M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-12-31 | $8.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $16.40M derived: sum of 2 quarters · filed 2025-03-03 | $24.19M derived: sum of 3 quarters · filed 2025-08-06 | $32.13M 10-K · filed 2025-03-03 |
| 2024-09-30 | $7.79M 10-Q · filed 2024-11-12 | $15.59M derived: sum of 2 quarters · filed 2025-08-06 | $23.53M 10-Q · filed 2024-11-12 | $29.06M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-06-30 | $7.79M 10-Q · filed 2025-08-06 | $15.73M 10-Q · filed 2025-08-06 | $21.27M derived: sum of 3 quarters · filed 2025-08-06 | $25.43M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $7.94M 10-Q · filed 2025-05-06 | $13.48M derived: sum of 2 quarters · filed 2025-05-06 | $17.64M derived: sum of 3 quarters · filed 2025-05-06 | $22.02M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $9.70M derived: sum of 2 quarters · filed 2025-03-03 | $14.08M derived: sum of 3 quarters · filed 2025-03-03 | $18.56M 10-K · filed 2025-03-03 |
| 2023-09-30 | $4.16M 10-Q · filed 2024-11-12 | $8.54M derived: sum of 2 quarters · filed 2024-11-12 | $13.03M 10-Q · filed 2024-11-12 | $16.48M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $4.38M 10-Q · filed 2024-08-08 | $8.87M 10-Q · filed 2024-08-08 | $12.31M derived: sum of 3 quarters · filed 2025-03-03 | $13.36M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $4.49M 10-Q · filed 2024-05-08 | $7.94M derived: sum of 2 quarters · filed 2025-03-03 | $8.98M derived: sum of 3 quarters · filed 2025-03-03 | $9.21M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $4.49M derived: sum of 2 quarters · filed 2025-03-03 | $4.72M derived: sum of 3 quarters · filed 2025-03-03 | $4.92M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.04M 10-Q · filed 2023-11-13 | $1.27M derived: sum of 2 quarters · filed 2023-11-13 | $1.47M 10-Q · filed 2023-11-13 | $1.60M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $227.00K 10-Q · filed 2023-08-08 | $423.00K 10-Q · filed 2023-08-08 | $561.00K derived: sum of 3 quarters · filed 2024-02-27 | $652.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $196.00K 10-Q · filed 2023-05-10 | $334.00K derived: sum of 2 quarters · filed 2024-02-27 | $425.00K derived: sum of 3 quarters · filed 2024-02-27 | $459.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $229.00K derived: sum of 2 quarters · filed 2024-02-27 | $263.00K derived: sum of 3 quarters · filed 2024-02-27 | $318.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $91.00K 10-Q · filed 2022-11-14 | $125.00K derived: sum of 2 quarters · filed 2022-11-14 | $180.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $34.00K 10-Q · filed 2022-08-15 | $89.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |